Literature DB >> 1794966

Update on the prognostic implication of morphology, histology, and karyotype in primary myelodysplastic syndromes.

G Verhoef1, C De Wolf-Peeters, S Kerim, J Van De Broeck, C Mecucci, H Van den Berghe, M Boogaerts.   

Abstract

The prognostic value of the FAB classification, bone marrow histology, Bournemouth score, and chromosome findings was studied in 88 patients with primary myelodysplastic syndromes. The median survival for the whole group of patients was 22 months (RA 61.7 months, RARS 31.6 months, CMML 15.7 months, RAEB 10.3 months, and RAEBt 8.2 months). Chromosomal abnormalities were found in 37 of the 70 patients investigated (52%). Only the differences in survival between patients with complex versus normal karyotype were statistically significant (p = 0.02). The presence of small blastic cells, located away from the endosteal surface (abnormal localization of immature blasts or ALIP) appears to be a major prognostic factor in predicting the duration of survival and progression to ANLL, especially in the FAB subgroups RA and RARS. Median survival for the 22 ALIP- cases with RA/RARS was 65 months, compared with 31 months for the ALIP+ cases (p = 0.0006). Nine ALIP+ patients (53%) developed ANLL in contrast to 3 (13%) of the ALIP- cases (p = 0.008). By redefining ALIP and evaluating the number and characteristics of the accompanying cells, histological subtypes were distinguished correlating largely with the FAB subgroups. Our findings demonstrate the prognostic importance of bone marrow biopsy and quantifying the complexity of bone marrow chromosome changes. It should be helpful in evaluating current attempts to find effective treatment for patients with MDS.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1794966

Source DB:  PubMed          Journal:  Hematol Pathol        ISSN: 0886-0238


  5 in total

Review 1.  Biology and treatment of myelodysplastic syndromes--developments in the past decade.

Authors:  R Willemze; W E Fibbe; J H Falkenburg; J C Kluin-Nelemans; P M Kluin; J E Landegent
Journal:  Ann Hematol       Date:  1993-03       Impact factor: 3.673

2.  Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features.

Authors:  G E Verhoef; C De Wolf-Peeters; A Ferrant; S Deprez; P Meeus; M Stul; P Zacheé; J J Cassiman; H Van den Berghe; M A Boogaerts
Journal:  Ann Hematol       Date:  1991-11       Impact factor: 3.673

3.  Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment.

Authors:  G E Verhoef; P Zachée; A Ferrant; H Demuynck; D Selleslag; L Van Hove; F Deckers; M A Boogaerts
Journal:  Ann Hematol       Date:  1992-01       Impact factor: 3.673

Review 4.  FAB classification of myelodysplastic syndromes: merits and controversies.

Authors:  G E Verhoef; S Pittaluga; C De Wolf-Peeters; M A Boogaerts
Journal:  Ann Hematol       Date:  1995-07       Impact factor: 3.673

5.  Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes.

Authors:  Rekha Chaubey; Sudha Sazawal; Rima Dada; Manoranjan Mahapatra; Renu Saxena
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.